Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × NSCLC × dacomitinib × Clear all

Phase

Status

Sponsor Class

Study Type

Observational 1 Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 14 Neoplasm Metastasis 6 Lung Neoplasms 3 Carcinoma, Squamous Cell 3 Brain Neoplasms 3 Squamous Cell Carcinoma of Head and Neck 2 Recurrence 2 Neoplasms 2 Head and Neck Neoplasms 2 Glioblastoma 2 Carcinoma 2 Triple Negative Breast Neoplasms 1 Thrombocytosis 1 Rare Tumor 1 Prostatic Neoplasms 1 Primary Myelofibrosis 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Penile Neoplasms 1 Pancreatic Neoplasms 1 Non-small Cell Lung Cancer Metastatic 1 NSCLC 1 Myeloproliferative Disorders 1 Myelodysplastic-Myeloproliferative Diseases 1 Myelodysplastic Syndromes 1 Multiple Myeloma 1 Mouth Neoplasms 1 Lymphoma, Non-Hodgkin 1 Leukemia, Myelomonocytic, Chronic 1 Leukemia, Myeloid, Chronic-Phase 1 Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1

Interventions

osimertinib 10 Pemetrexed 10 Carboplatin 10 aflutinib 8 Drug Therapy 7 Radiotherapy 6 Gefitinib 6 anlotinib 5 Docetaxel 5 Cisplatin 5 Vinorelbine 4 Radiosurgery 4 Paclitaxel 4 Gemcitabine 4 tislelizumab 3 pembrolizumab 3 icotinib 3 apatinib 3 HM781-36B 3 Erlotinib Hydrochloride 3 toripalimab 2 spartalizumab 2 Tyrosine Kinase Inhibitors 2 Thalidomide 2 Surgical Procedures, Operative 2 S 1 (combination) 2 Platinum 2 Immune Checkpoint Inhibitors 2 HMPL-013 2 Chemotherapy, Adjuvant 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04811001 2023-02-21

CAPLAND

Fondazione Ricerca Traslazionale

Phase 2 Unknown

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡